drugset / Trial / NCT02545413

Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome

NCT02545413

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Irritable bowel syndrome (IBS) is the most common functional GI disorder in which abdominal pain and/or discomfort is associated with changes in bowel habit, and with features of disordered defecation. IBS affects 10-20% of the population and causes a marked reduction of quality of life in affected individuals.The high prevalence of IBS is accompanied by large societal economic burdens and negative effects on the quality of life in affected patients. It is divided into 3 types IBS-D diarrhea predominant, IBS-C constipation predominant, IBS-M mixed sub type.

Timeline

Start
2016-05
Primary completion
2017-06
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VSL#3 Other / unclassified 1.125e+11 cells